From a translational perspective, clinical efficacy of PD-1/PD-L1 antibodies in solid tumors is frequently constrained by limited tumor penetration, the occurrence of immune-related adverse events associated with systemic immune activation, and substantial production costs [38]. This evidence concerns the gene CD274 and neoplasm.